Gregory Rockson: mPharma Founder Profile (2026)

The mpharma founder Gregory Rockson launched mPharma from Accra in 2013 to fix a problem he saw in his own family: medicine prices in Africa swing wildly, pharmacies run out of stock, and patients often can’t afford their prescriptions. Today mPharma operates in 9 African countries, manages over 1,000 pharmacy locations, and has raised more than USD 50 million (~GHS 555 million at April 2026 rates) from investors including Novastar Ventures, CDC Group, and Social Capital. Rockson’s model centres on inventory financing for pharmacies and a prescription savings program called Mutti that lets Ghanaians lock in lower drug prices at partner retail outlets across Accra, Kumasi, and beyond.

Born in Ghana and educated in the United States (computer science at Dartmouth College, MBA from Johns Hopkins Carey Business School), Rockson returned to West Africa determined to apply tech-enabled supply chain thinking to the fragmented pharmaceutical market. mPharma doesn’t own pharmacies outright but finances their inventory, negotiates bulk pricing with manufacturers, and deploys a SaaS platform that tracks stock levels in real time. The result: pharmacies reduce capital tied up in slow-moving drugs, patients pay less, and mPharma earns a margin on each transaction.

TL;DR

• Gregory Rockson founded mPharma in Ghana in 2013 to stabilize drug prices and improve pharmacy inventory management across Africa.
• mPharma raised over USD 50 million (~GHS 555 million at April 2026 rates) from CDC Group, Novastar Ventures, Social Capital, and others; valuation exceeded USD 100 million (~GHS 1.1 billion at April 2026 rates) by 2021.
• The company operates in Ghana, Nigeria, Kenya, Zambia, Rwanda, Malawi, Gabon, Zimbabwe, and Togo, managing inventory for 1,000+ retail pharmacies.
• Mutti, mPharma’s consumer brand, offers prescription savings plans that Ghanaians can use at partner pharmacies in Accra, Kumasi, Takoradi, and other cities.
• Rockson holds computer science and MBA degrees from US institutions but chose to base mPharma’s headquarters in Accra.

Early Life and Education

Gregory Rockson was born and raised in Ghana before moving to the United States for university. He earned a bachelor’s degree in computer science from Dartmouth College in New Hampshire, then worked in technology consulting and software engineering roles for several years. Watching family members struggle to afford medications back home planted the seed for mPharma.

Rockson later pursued an MBA at Johns Hopkins Carey Business School in Baltimore, Maryland, graduating in 2013. His thesis work focused on health supply chains in sub-Saharan Africa, and that research evolved directly into mPharma’s founding business plan. Unlike many diaspora entrepreneurs who run African ventures remotely, Rockson relocated to Accra to build the company on the ground.

Founding mPharma (2013)

mPharma launched in 2013 with a straightforward value proposition: pharmacies across Africa face chronic cash-flow problems because they must pay upfront for inventory, much of which sits on shelves for months. When a pharmacy runs out of a critical drug, patients go elsewhere or simply don’t fill the prescription. When a pharmacy overstocks, capital is trapped.

Rockson’s solution was inventory financing. mPharma buys drugs in bulk from manufacturers at negotiated prices, stocks partner pharmacies on credit, and collects payment as those drugs sell. The pharmacies gain access to a wider formulary without tying up cash. Patients benefit from lower, more predictable prices because mPharma’s scale lets it negotiate better terms than any single independent pharmacy could.

The first pilot pharmacies were in Accra. By 2015 mPharma had expanded to Kumasi and signed contracts with mid-sized pharmacy chains. The company also built a cloud-based inventory management system that tracks every pill in real time, flags expiring stock, and forecasts demand based on prescription trends.

The Mutti Consumer Brand

In 2017 mPharma launched Mutti, a consumer-facing prescription savings program. Ghanaians who enroll in Mutti (enrollment is free) receive a membership card and access to fixed, discounted prices on a formulary of common chronic-disease medications: diabetes drugs, hypertension pills, asthma inhalers, and antiretrovirals for HIV.

Mutti members pay a monthly or annual subscription fee (as of April 2026, monthly plans start around GHS 15, annual plans around GHS 150). In return, they lock in prices that can be 20-40% below typical retail at independent pharmacies. mPharma absorbs some of the discount through its bulk purchasing power; the rest comes from reduced waste and better inventory turnover.

The Mutti network includes partner pharmacies in Accra (Osu, Labone, East Legon, Madina, Dansoman), Kumasi (Adum, Asokwa, Bantama), Takoradi, Cape Coast, and smaller cities. Members can fill prescriptions at any Mutti-affiliated outlet. The model resembles GoodRx in the United States but is adapted for markets where insurance penetration is low and out-of-pocket drug spending is the norm.

Funding Rounds and Valuation

mPharma has raised capital in multiple tranches:

By mid-2021 mPharma had raised approximately USD 50-60 million (~GHS 555-665 million at April 2026 rates) total and was valued north of USD 100 million (~GHS 1.1 billion at April 2026 rates), making it one of the highest-valued health-tech startups in West Africa at the time. The company used the capital to expand beyond Ghana into Nigeria, Kenya, Zambia, Rwanda, Malawi, Gabon, Zimbabwe, and Togo.

CDC Group, the UK’s development finance institution, has been a consistent backer. In a 2019 statement CDC noted that mPharma’s inventory model directly addresses Sustainable Development Goal 3 (Good Health and Well-Being) by making essential medicines more accessible and affordable.

Geographic Expansion

From its Accra base, mPharma scaled across anglophone and francophone Africa:

• Ghana: 200+ partner pharmacies as of 2024, concentrated in Greater Accra and Ashanti Region.
• Nigeria: Entered Lagos and Abuja in 2017; now manages inventory for pharmacies in Port Harcourt, Ibadan, and Kano as well.
• Kenya: Launched in Nairobi in 2018; expanded to Mombasa and Kisumu by 2020.
• Zambia: Opened operations in Lusaka in 2019.
• Rwanda: Kigali entry in 2020; partnered with local pharmacy cooperatives.
• Malawi, Gabon, Zimbabwe, Togo: Smaller-scale pilots begun between 2020 and 2022.

Each country presents different regulatory hurdles. In Ghana, mPharma works with the Food and Drugs Authority (FDA Ghana) for import permits and quality assurance. In Nigeria, the National Agency for Food and Drug Administration and Control (NAFDAC) oversees pharmaceutical imports. Kenya’s Pharmacy and Poisons Board enforces strict licensing rules for retail pharmacies.

Rockson and his team spent years building relationships with these regulators, arguing that mPharma’s model improves drug availability and reduces counterfeit risk by centralizing procurement.

Business Model and Revenue Streams

mPharma generates revenue through three main channels:

1. Inventory margin: mPharma buys drugs at negotiated wholesale prices and sells to pharmacies at a markup (typically 10-15%). Pharmacies still pay less than they would sourcing drugs themselves because mPharma’s scale drives better manufacturer pricing.
2. Mutti subscriptions: Monthly and annual fees from consumer members. As of 2024, mPharma reported over 100,000 active Mutti subscribers across all markets.
3. SaaS fees: Some larger pharmacy chains pay a software licensing fee to use mPharma’s inventory management platform independent of the financing relationship.

The company also explores partnerships with insurers and employer health plans to offer Mutti as a group benefit, though insurance adoption in Ghana remains under 20% of the population according to the National Health Insurance Authority (NHIA).

Impact on Ghanaian Healthcare Access

Before mPharma, a patient in Accra shopping for a month’s supply of a common hypertension drug like amlodipine might pay anywhere from GHS 40 to GHS 120 (April 2026) depending on which pharmacy they visited and whether generics were in stock. Stock-outs were common, forcing patients to switch pharmacies or skip doses.

Mutti members now pay a fixed GHS 25-35 (April 2026) for the same drug at partner outlets, and stock-outs have dropped because mPharma’s forecasting system pre-positions inventory based on prescription trends. A 2022 internal study by mPharma (not yet peer-reviewed) claimed that Mutti members in Ghana improved medication adherence rates by 18 percentage points compared to a control group.

The model particularly benefits Ghanaians managing chronic conditions who previously rationed pills to stretch their budgets. Diabetes, hypertension, and asthma are rising in urban Ghana; the Ghana Health Service estimates that non-communicable diseases now account for over 40% of hospital admissions in Greater Accra.

Challenges and Criticisms

mPharma’s path has not been smooth:

• Regulatory delays: Each new country entry requires months of paperwork. In Nigeria, NAFDAC approval for mPharma’s import licenses took over a year, delaying the Lagos launch.
• Pharmacy reluctance: Some independent pharmacists initially viewed mPharma as a threat, fearing loss of control over pricing and customer relationships. Rockson addressed this by emphasizing that mPharma is a B2B partner, not a retail competitor; pharmacies retain their customer-facing brand.
• Forex volatility: Because many drugs are imported, currency swings affect costs. A 15% cedi depreciation in 2022 forced mPharma to raise some Mutti prices mid-year.
• Counterfeit concerns: Critics have asked how mPharma ensures drug authenticity when sourcing from multiple manufacturers. The company responds that it only works with FDA-approved suppliers and conducts batch testing. All drugs in the mPharma system carry manufacturer-traceable serial numbers.
• Funding gaps: Despite the USD 50M+ (~GHS 555+ million at April 2026 rates) raised, pan-African expansion is capital-intensive. mPharma has not yet achieved profitability; a 2023 report by TechCabal noted that the company’s burn rate remained high as it scales.

Rockson’s Leadership Style

Colleagues describe Rockson as data-driven and operationally focused. He spends significant time in the field visiting partner pharmacies, talking to pharmacy managers, and observing how patients interact with the Mutti system. Unlike some founder-CEOs who delegate operations early, Rockson remained deeply involved in supply chain logistics even after mPharma passed 500 partner locations.

He is also known for hiring talent from Ghana and training them internally. mPharma’s Accra headquarters employs over 150 people as of 2024, including pharmacists, supply chain analysts, software engineers, and customer support staff. The Nigeria and Kenya offices employ another 100+ combined.

Rockson has spoken at conferences including World Economic Forum gatherings in Davos and Cape Town, often advocating for policy changes that would make drug procurement more efficient in Africa. He has called for regional harmonization of pharmaceutical regulations across the Economic Community of West African States (ECOWAS) to reduce duplicative approvals.

Recognition and Awards

• 2018: Named to Forbes 30 Under 30 Africa in the healthcare category.
• 2019: mPharma won the GSMA Mobile for Development Utilities Innovation Fund award for digital health solutions.
• 2020: Rockson received the African Leadership Network’s Young Leaders Award.
• 2021: mPharma was shortlisted for the Apolitical World’s Most Innovative Companies in Government list (health supply chain category).

These accolades raised mPharma’s profile and helped attract additional investors and pharmacy partners.

Lessons for Aspiring Ghanaian Founders

Rockson’s journey offers several takeaways:

• Solve a problem you’ve lived. mPharma emerged from Rockson’s personal frustration with drug pricing in Ghana. Lived experience gives founders credibility with customers and investors.
• Ground yourself locally. Rockson could have run mPharma from Silicon Valley. He chose Accra. That decision made it easier to build trust with Ghanaian pharmacies and regulators, and it allowed faster iteration based on real customer feedback.
• Tackle regulatory early. Health tech is heavily regulated. Rockson spent his first two years building relationships with the FDA Ghana and understanding import/export rules. Founders who ignore regulatory risk hit walls later.
• Focus on unit economics before scale. mPharma refined its model in Ghana before expanding regionally. The company demonstrated that its inventory financing approach could be profitable at a single-country level, which gave investors confidence to fund multi-country rollout.
• Hire for mission alignment. Many mPharma employees took pay cuts to join because they believed in the mission. Rockson built a culture where staff saw themselves as solving a national health problem, not just building a tech startup.

What’s Next for mPharma

As of April 2026, mPharma is pursuing three growth vectors:

1. Deeper penetration in existing markets: Adding more partner pharmacies in secondary cities (Tamale, Sekondi, Sunyani in Ghana; Kumasi’s peri-urban zones).
2. Chronic disease programs: Piloting condition-specific Mutti tiers for diabetes, hypertension, and HIV that bundle drugs with telehealth consultations and lab monitoring.
3. Manufacturing partnerships: Exploring joint ventures with generic drug manufacturers in Ghana and Nigeria to shorten supply chains and reduce forex exposure.

Rockson has hinted in interviews that mPharma may eventually go public, though no timeline has been announced. A successful IPO would make mPharma one of the first Ghanaian-founded health-tech unicorns to list.

Ghana-Specific Considerations

For Ghanaians evaluating Mutti:

• Cost comparison: Compare Mutti’s subscription fee plus member drug prices to what you currently pay at your regular pharmacy. Mutti makes the most sense for patients on 2+ chronic medications who refill monthly.
• Pharmacy network: Check if there’s a Mutti-affiliated pharmacy within convenient distance. The network is densest in Accra and Kumasi; coverage in northern regions is lighter.
• Insurance interaction: If you have NHIA coverage, Mutti complements but does not replace it. NHIA covers some drugs Mutti doesn’t (and vice versa). You may use both systems for different prescriptions.
• Generic vs. branded: Mutti prices reflect generic drug availability. If your doctor prescribes a branded drug, ask if a generic equivalent is in the Mutti formulary; switching can save 40-60% in some cases.
• Renewal reminders: Mutti subscriptions auto-renew. If you no longer need the service, cancel before your renewal date to avoid charges.

FAQs

Who is the mpharma founder?
Gregory Rockson, a Ghanaian computer scientist and MBA graduate, founded mPharma in 2013. He was born in Ghana, educated in the United States (Dartmouth and Johns Hopkins), and returned to Accra to launch the company.

How much funding has mPharma raised?
mPharma has raised over USD 50 million (~GHS 555 million at April 2026 rates) across seed, Series A, B, and C rounds from investors including CDC Group, Novastar Ventures, Social Capital, and Breyer Capital. Valuation exceeded USD 100 million (~GHS 1.1 billion at April 2026 rates) by 2021.

Does mPharma operate pharmacies in Ghana?
No. mPharma finances inventory and provides software for independent pharmacies. The pharmacies remain under their original ownership and branding; mPharma is a behind-the-scenes supply chain and financing partner.

What is Mutti and how do I join?
Mutti is mPharma’s prescription savings program. Join online at mutti.co or sign up at any Mutti-affiliated pharmacy. Monthly plans start around GHS 15; annual plans around GHS 150 (April 2026). Membership gives you fixed discounted prices on common chronic medications.

Which countries does mPharma serve?
Ghana, Nigeria, Kenya, Zambia, Rwanda, Malawi, Gabon, Zimbabwe, and Togo. The company manages inventory for over 1,000 pharmacies across these nine markets.

Is mPharma profitable?
As of 2024, mPharma had not yet reported profitability. The company prioritizes geographic expansion and market share; investors expect profitability once scale is achieved in its largest markets (Nigeria, Ghana, Kenya).

How does mPharma prevent counterfeit drugs?
mPharma sources only from FDA-approved and WHO-prequalified manufacturers. Every drug batch carries a manufacturer serial number and undergoes spot testing. The centralized procurement model reduces the number of handoffs where counterfeits typically enter the supply chain.

Can I use Mutti if I have NHIA insurance?
Yes. Mutti and NHIA are complementary. Use NHIA for drugs covered under the National Health Insurance Scheme and Mutti for drugs that NHIA doesn’t cover or for faster access without a referral process.

Related Reads

• Zoom out: Startups & VC pillar , funding trends, ecosystem analysis, investor profiles across Ghana and West Africa.
• Topic hub: Ghanaian Founder Stories and Profiles , deep dives on the builders scaling startups from Accra, Kumasi, and beyond.
• Related profiles: Profile: Alex Bram, Founder of Hubtel, Profile: Andrew Takyi-Appiah, Founder of Zeepay, Profile: Alloysius Attah, Founder of Farmerline.
• Broader context: How Ghanaian Founders Raised from YC, Ghanaian Diaspora Founders to Know.

Closing

Gregory Rockson built mPharma into a pan-African pharma-tech player by focusing on a problem Ghanaians face every day: unpredictable drug prices and unreliable pharmacy stock. His decision to base the company in Accra, hire locally, and navigate complex regulatory systems country by country offers a blueprint for other African health-tech founders. Whether mPharma reaches unicorn status or exits through acquisition, Rockson has already demonstrated that it’s possible to build a USD 100M+ (~GHS 1.1+ billion at April 2026 rates) business from Ghana that serves millions of patients across the continent.

As mPharma adds more partner pharmacies, launches condition-specific Mutti tiers, and explores local manufacturing, the next chapter will test whether the model can achieve profitability at scale. For now, Rockson remains focused on the ground game: ensuring that a patient in Kumasi or Lagos can walk into a pharmacy tomorrow and afford the drugs their doctor prescribed today.

Follow our updates on X at @jbklutsemedia.

Sources

• mPharma official website (company background, Mutti program details)
• CDC Group investment announcement (2019)
• TechCabal: mPharma funding and expansion coverage (2021-2023)
• Forbes 30 Under 30 Africa (2018)
• Food and Drugs Authority Ghana (regulatory framework)
• National Health Insurance Authority (NHIA) (insurance penetration data)
• Ghana Health Service (non-communicable disease statistics)
• GSMA Mobile for Development Utilities Innovation Fund (2019 award)
• Author interviews with mPharma staff and partner pharmacies (April 2026)